OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1

High-affinity uptake of natural nucleosides as well as nucleoside derivatives used in anticancer therapies is mediated by human concentrative nucleoside transporters (hCNTs). hCNT1, the hCNT family member that specifically transports pyrimidines, is also a transceptor involved in tumor progression....

ver descrição completa

Detalhes bibliográficos
Autores: Boces-Pascual, C, Mata-Ventosa, A, Martin-Satue, M, Boix, L, Gironella, M, Pastor-Anglada, M, Perez-Torras, S
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2021
País:España
Recursos:Fundació Sant Joan de Déu
Repositório:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p20189
Acesso em linha:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20189
Access Level:Acceso aberto
Palavra-chave:Non-coding RNA
Nucleoside analog
Nucleoside transporter
CNT1
Chemoresistance
id ES_d62ed1d8c071ca2e9cbb6f89fa940187
oai_identifier_str oai:fsjd.fundanetsuite.com:p20189
network_acronym_str ES
network_name_str España
repository_id_str
spelling OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1Boces-Pascual, CMata-Ventosa, AMartin-Satue, MBoix, LGironella, MPastor-Anglada, MPerez-Torras, SNon-coding RNANucleoside analogNucleoside transporterCNT1ChemoresistanceHigh-affinity uptake of natural nucleosides as well as nucleoside derivatives used in anticancer therapies is mediated by human concentrative nucleoside transporters (hCNTs). hCNT1, the hCNT family member that specifically transports pyrimidines, is also a transceptor involved in tumor progression. In particular, oncogenesis appears to be associated with hCNT1 downregulation in some cancers, although the underlying mechanisms are largely unknown. Here, we sought to address changes in colorectal and pancreatic ductal adenocarcinoma-both of which are important digestive cancers-in the context of treatment with fluoropyrimidine derivatives. An analysis of cancer samples and matching non-tumoral adjacent tissues revealed downregulation of hCNT1 protein in both types of tumor. Further exploration of the putative regulation of hCNT1 by microRNAs (miRNAs), which are highly deregulated in these cancers, revealed a direct relationship between the oncomiRs miR-106a and miR-17 and the loss of hCNT1. Collectively, our findings provide the first demonstration that hCNT1 inhibition by these oncomiRs could contribute to chemoresistance to fluoropyrimidine-based treatments in colorectal and pancreatic cancer. [GRAPHICS] .SPRINGER BASEL AG2021info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20189CELLULAR AND MOLECULAR LIFE SCIENCESISSN: 1420682XISSNe: 14209071reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déuinstname:Fundació Sant Joan de DéuInglésinfo:eu-repo/semantics/openAccessoai:fsjd.fundanetsuite.com:p201892026-05-27T12:37:41Z
dc.title.none.fl_str_mv OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1
title OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1
spellingShingle OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1
Boces-Pascual, C
Non-coding RNA
Nucleoside analog
Nucleoside transporter
CNT1
Chemoresistance
title_short OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1
title_full OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1
title_fullStr OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1
title_full_unstemmed OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1
title_sort OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1
dc.creator.none.fl_str_mv Boces-Pascual, C
Mata-Ventosa, A
Martin-Satue, M
Boix, L
Gironella, M
Pastor-Anglada, M
Perez-Torras, S
author Boces-Pascual, C
author_facet Boces-Pascual, C
Mata-Ventosa, A
Martin-Satue, M
Boix, L
Gironella, M
Pastor-Anglada, M
Perez-Torras, S
author_role author
author2 Mata-Ventosa, A
Martin-Satue, M
Boix, L
Gironella, M
Pastor-Anglada, M
Perez-Torras, S
author2_role author
author
author
author
author
author
dc.subject.none.fl_str_mv Non-coding RNA
Nucleoside analog
Nucleoside transporter
CNT1
Chemoresistance
topic Non-coding RNA
Nucleoside analog
Nucleoside transporter
CNT1
Chemoresistance
description High-affinity uptake of natural nucleosides as well as nucleoside derivatives used in anticancer therapies is mediated by human concentrative nucleoside transporters (hCNTs). hCNT1, the hCNT family member that specifically transports pyrimidines, is also a transceptor involved in tumor progression. In particular, oncogenesis appears to be associated with hCNT1 downregulation in some cancers, although the underlying mechanisms are largely unknown. Here, we sought to address changes in colorectal and pancreatic ductal adenocarcinoma-both of which are important digestive cancers-in the context of treatment with fluoropyrimidine derivatives. An analysis of cancer samples and matching non-tumoral adjacent tissues revealed downregulation of hCNT1 protein in both types of tumor. Further exploration of the putative regulation of hCNT1 by microRNAs (miRNAs), which are highly deregulated in these cancers, revealed a direct relationship between the oncomiRs miR-106a and miR-17 and the loss of hCNT1. Collectively, our findings provide the first demonstration that hCNT1 inhibition by these oncomiRs could contribute to chemoresistance to fluoropyrimidine-based treatments in colorectal and pancreatic cancer. [GRAPHICS] .
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20189
url https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20189
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER BASEL AG
publisher.none.fl_str_mv SPRINGER BASEL AG
dc.source.none.fl_str_mv CELLULAR AND MOLECULAR LIFE SCIENCES
ISSN: 1420682X
ISSNe: 14209071
reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname:Fundació Sant Joan de Déu
instname_str Fundació Sant Joan de Déu
reponame_str r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
collection r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420814795800576
score 15.812455

Registros relacionados